Johnson & Johnson Covid-19 vaccine enters Phase 3 trial in U.S.
Has entered the final phase of testing for a covert 19 vaccine. Johnson and Johnson confirms entering critical Phase three and plans to enroll 60,000 participants as they move forward. CBS NEWS Medical contributor Dr David Vegas says the vaccine has an advantage over the other ones being developed. It's an easier vaccine that other vaccines and that this vaccine is One shot and the other vaccines have been two shots. Vaccine does not have to be stored in sub zero temps, which is a plus, Vega says. While a trial reaching faith three is great News of Copan 19 vaccine will still not be available until next year. Maria Garcia CBS news